1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D...

Details 1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D... 1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D...

2007-04-05

2011-11-15

Qazi, Sabiha (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

C552S653000

Reexamination Certificate

active

08058265

ABSTRACT:
Disclosed are 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds, pharmaceutical compositions, and methods of making and treatment thereof. The compounds are generally directed to biologically active 2-alkylidene-19-nor-vitamin D compounds and analogs thereof characterized by the presence of a 3′-hydroxypropylidene moiety at C-2 and the presence of an abbreviated alkyl side-chain free of any hydroxyl moiety.

REFERENCES:
patent: 4666634 (1987-05-01), Miyamoto et al.
patent: 5086191 (1992-02-01), DeLuca et al.
patent: 5237110 (1993-08-01), DeLuca et al.
patent: 5246925 (1993-09-01), DeLuca et al.
patent: 5536713 (1996-07-01), Deluca et al.
patent: 5587497 (1996-12-01), DeLuca et al.
patent: 5817648 (1998-10-01), Kutner et al.
patent: 5843927 (1998-12-01), DeLuca et al.
patent: 5843928 (1998-12-01), Deluca et al.
patent: 5877168 (1999-03-01), Miyamoto et al.
patent: 5936133 (1999-08-01), Deluca et al.
patent: 5945410 (1999-08-01), DeLuca et al.
patent: 6392071 (2002-05-01), DeLuca et al.
patent: 6537981 (2003-03-01), DeLuca et al.
patent: 6806262 (2004-10-01), DeLuca et al.
patent: 6846811 (2005-01-01), DeLuca et al.
patent: 6992074 (2006-01-01), DeLuca et al.
patent: 7541348 (2009-06-01), DeLuca et al.
patent: 2004/0229851 (2004-11-01), DeLuca et al.
patent: 2005/0119242 (2005-06-01), DeLuca et al.
patent: 2006/0135799 (2006-06-01), DeLuca et al.
patent: 0078704 (1987-04-01), None
patent: 0184206 (1989-04-01), None
patent: 0387077 (1994-01-01), None
patent: 0480572 (1995-06-01), None
patent: 0516410 (1998-07-01), None
patent: 0474517 (1998-11-01), None
patent: 1524264 (2005-04-01), None
patent: 6041059 (1994-02-01), None
patent: WO 90/09991 (1990-09-01), None
patent: WO 01/92221 (2001-12-01), None
patent: WO 2004/092118 (2004-10-01), None
patent: WO 2004/092118 (2004-10-01), None
patent: WO 2005/051323 (2005-06-01), None
patent: WO 2006/057913 (2006-06-01), None
patent: WO 2006/057914 (2006-06-01), None
patent: WO 2007/117563 (2007-10-01), None
Jimenez, J.J., et al., “Treatment with ImuVert/N-Acetylcysteine Protects Rats from Cyclophosphamide/Cytarabine-Induced . . . ,” Cancer Investigation 10:271-276(1992).
Sredni, B., et al., “The Protective Role of the Immunomodulator AS101 Against Chemotherapy-Induced Alopecia Studies on Human . . . ,” Int. J. Cancer 65:97-103 (1996).
Xia, C., et al., “The organization of the human GSTP1-1 gene promoter and its response to retinoic acid and cellular redox status,” Biochem. J. 313:155-161 (1996).
Arbour, Nancy C. et al., “A Highly Sensitive Method for Large-Scale Measurements of 1,25-Dihydroxyvitamin D,” Analytical Biochemistry, 1998, vol. 255, pp. 148-154.
Arbour, Nancy C. et al., “TLR4mutations are associated with endotoxin hyporesponsiveness in humans,” Nature Genetics, Jun. 2000, vol. 25, pp. 187-191.
Baggiolini, Enrico G. et al., “Stereocontrolled Total Synthesis of 1α,25-Dihydroxycholecalciferol and 1α,25-Dihydroxyergocalciferol,” J. Org. Chem., 1986, vol. 51, pp. 3098-3108.
Bouillon, Roger et al., “Biological Activity of Dihydroxylated 19-Nor-(Pre) Vitamin D3,” Journal of Bone and Mineral Research, 1993, vol. 8, No. 8, pp. 1009-1015.
Collins, S. J. et al., “Normal Functional Characteristics of Cultured Human Promyelocytic Leukemia Cells (HL-60) After Induction of Differentiation by Dimethylsulfoxide,” J. Exp. Med., 1979, vol. 149, pp. 969-974.
Dame, Margaret C. et al., “Monoclonal Antibodies to the Porcine Intestinal Receptor for 1,25-Dihydroxyvitamin D3: Interaction with Distinct Receptor Domains,” Biochemistry, 1986, vol. 25, pp. 4523-4534.
Fall, Yagamare et al., “Vitamin D heterocyclic analogues. Part 1: A stereoselective route to CD systems with pyrazole rings in their side chains,” Tetrahedron Letters, 2002, No. 43, pp. 1433-1436.
Fujishima, Toshie et al., “Synthesis and Biological Activity of 2-Methyl-20-EPI Analogues of 1a,25-Dihydroxyvitamin D3,” Bioorganic & Medicinal Chemistry Letters, 1998, vol. 8, pp. 2145-2148.
Glebocka, Agnieszka et al., “New derivative of 1α,25-dihydroxy-19-norvitamin D3with 3'-alkoxypropylidene moiety at C-2: synthesis, biological activity and conformational analysis,” J. Steroid Biochem. Mol. Biol., 2004, vol. 89-90, pp. 25-30.
Granja, Juan R. et al., “Studies on the Opening of Dioxanone and Acetal Templates and Applications to the Synthesis of 1α,25-Dihydroxyvitamin D2,” J. Org. Chem., 1993, vol. 58, pp. 124-131.
International Preliminary Report on Patentability and Written Opinion for PCT/US2007/008525 dated Oct. 8, 2008.
International Search Report and Written Opinion for PCT/US2007/008525 mailed Oct. 5, 2007.
Kiegiel, Jaroslaw et al., “Chemical Conversion of Vitamin D3to its 1.25-Dihydroxy Metabolite,” Tetrahedron Letters, 1991, vol. 32, No. 43, pp. 6057-6060.
Konno, Katsuhiro et al., “A Novel and Practical Route to A-Ring Enyne Synthon for 1a,25-Dihydroxyvitamin D3Analogs: Synthesis of A-ring Diastereomers of 1a,25-Dihydroxy-Vitamin D3and 2-Methyl-1,25-Dihydroxyvitamin D3,” Bioorganic & Medicinal Chemistry Letters, 1998, vol. 8, pp. 151-156.
Lythgoe, B., “Synthetic Approaches to Vitamin D and its Relatives,” Chem. Soc. Rev. 9, pp. 449-475.
Lythgoe, Basil et al., “Calciferol and its Relatives. Part 22. A Direct Total Synthesis of Vitamin D2and Vitamin D3,” J. Chem. Soc. Perkin Trans. I, 1978, pp. 590-595.
Mascarenas, J. L. et al., “Studies on the Synthesis of Side-Chain Hydroxylated Metabolites of Vitamind D. 3. Synthesis of 25-Ketovitamin D3and 25-Hydroxyvitamin D3,” J. Org. Chem., 1986, vol. 51, pp. 1269-1272.
Miyamoto, K., “Pharmaceuticals containing vitamin D3 derivatives for regulating calcium metabolism”, Chemical Abstracts, Mar. 6, 1989, vol. 110: 82505v, No. 10, pp. 462-463.
Miyamoto, K., “2β-Substituted vitamin D derivatives”, Chemical Abstracts, Nov. 21, 1994, vol. 121: 256121m, No. 21.
Okano, Toshio et al., “Regulatory Activities of 2β-(3-Hydroxypropoxy)-1a,25-Dihydroxyvitamin D3, A Novel Synthetic Vitamin D3Derivative, on Calcium Metabolism,” Biochemical and Biophysical Research Communications, Sep. 29, 1989, vol. 163, No. 3, pp. 1444-1449.
Ostrem, Voula K. et al., “24- and 26-homo-1,25-dihydroxyvitamin D3: Preferential activity in inducing differentiation of human leukemia cells HL-60 in vitro,” Proc. Natl. Acad. Sci. USA, May 1987, vol. 84, pp. 2610-2614.
Ostrem, Voula K. et al., “Induction of Monocytic Differentiation of HL-60 Cells by 1,25-Dihydroxyvitamin D Analogs,” The Journal of Biological Chemistry, Oct. 15, 1987, vol. 262, No. 29, pp. 14164-14171.
Perlman, Kato L. et al., “1α,25-Dihydroxy-19-Nor-Vitamin D3, A Novel Vitamin D-related Compound with Potential Therapeutic Activity,” Tetrahedron Letters, 1990, vol. 31, No. 13, pp. 1823-1824.
Perlman, Kato L. et al., “Novel Synthesis of 19-Nor-Vitamin D Compounds,” Tetrahedron Letters, 1991, vol. 32, No. 52, pp. 7663-7666.
Plum, Lori A. et al., “Biologically active noncalcemic analogs of 1α,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl,” PNAS, May 4, 2004, vol. 101, No. 81, pp. 6900-6904.
Posner, Gary H. et al., “2-Fluoroalkyl A-Ring Analogs of 1,25-Dihydroxyvitamin D3Stereocontrolled Total Synthesis via Intramolecular and Intermolecular Diels-Alder Cycloadditions. Preliminary Biological Testing,” J. of Org. Chem., 1995, vol. 60, pp. 4617-4628.
Posner, Gary H. et al., “Stereocontrolled Synthesis of a Trihydroxylated a Ring as an Immediate Precursor to 1a,2a,25-Trihydroxovitamin D3,” J. Org. Chem., 1991, vol. 56, pp. 4339-4341.
Sarandeses, Luis A. et al., “Synthesis of 1a,25-Dihydroxy-19-Norprevitamin D3,” Tetrahedron Letters, 1992, vol. 33, No. 37, pp. 5445-5448.
Sardina, F. Javier et al., “Studies on the Sy

Affiliated with

Also associated with

Rating

1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4303778